Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

A Study of Combination Therapy With PEGASYS (Pegylated Interferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response

15. juli 2013 oppdatert av: Hoffmann-La Roche

A Randomized, Open-label Study of the Effects of 24 vs 48 Weeks of Combination Therapy With PEGASYS (Peginterferon Alfa-2a 40KD) Plus COPEGUS (Ribavirin) on Sustained Virological Response in Patients With Chronic Hepatitis C, Genotype 2 or 3 Who do Not Achieve a Rapid Viral Response

This study will evaluate the efficacy and safety of peginterferon alfa-2a 40KD + ribavirin combination therapy given for 24 weeks versus 48 weeks in patients with chronic hepatitis C, genotype 2/3.

Studieoversikt

Status

Fullført

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

During a pre-study run-in phase patients with chronic hepatitis C genotype 2/3, who had started therapy with PEG-IFN alfa-2a plus ribavirin according to local standard of care and did not achieve a rapid viral response (RVR) (defined as Hepatitis C virus (HCV) RNA <15 IU/mL at Week 4 of treatment measured with the Roche COBAS AmpliPrep / COBAS TaqMan® HCV Test) were eligible for the study and entered the screening phase between treatment Week 4 and 8 as soon as the result of the Week 4 HCV RNA test was available.

Eligible patients entered the study and continued with the dose regimens of PEG-IFN alfa-2a and ribavirin they were taking prior to enrolment into the trial up to Week 24 of treatment. Patients who achieved at least a 2-log10 drop of HCV RNA at Week 12 (as compared to HCV RNA levels prior to treatment initiation) or had HCV RNA <15 IU/mL, and who were still taking study medication at treatment Week 24, were randomized at treatment Week 24 to one of the two study groups. Upon randomization, participants either stopped treatment (equaling 24 weeks of treatment) or continued treatment for another 24 weeks (equaling 48 weeks of treatment). A treatment free follow-up period of 24 weeks (for participants in the 48-week treatment group) or 48 weeks (participants in the 24-week treatment group) completed the study.

Studietype

Intervensjonell

Registrering (Faktiske)

235

Fase

  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

  • Australia
      • Darlinghurst, Australia, 2010
      • Fremantle, Australia, 6160
      • Melbourne, Australia, 3186
      • Nedlands, Australia, 6009
      • Sydney, Australia, 2139
  • Belgia
      • Antwerpen, Belgia, 2650
      • Bruxelles, Belgia, 1020
      • Bruxelles, Belgia, 1070
      • Bruxelles, Belgia, 1000
      • Gent, Belgia, 9000
      • Kortrijk, Belgia, 8500
      • Liege, Belgia, 4000
  • Brasil
      • Brasilia, Brasil, 70335-000
      • Campinas, Brasil, 13081-970
      • Campinas, Brasil, 13012-970
      • Porto Alegre, Brasil, 90020-090
      • Porto Alegre, Brasil, 90035-003
      • Ribeirao Preto, Brasil, 14049-900
      • Rio de Janeiro, Brasil, 20020-022
      • Santo Andre, Brasil, 09060-650
      • Sao Luis, Brasil, 78048-790
      • Sao Paulo, Brasil, 04040-003
      • Sorocaba, Brasil, 18047-600
      • Vitoria, Brasil, 29043-260
  • Canada
    • Alberta
      • Edmonton, Alberta, Canada, T6G 2B7
    • British Columbia
      • Vancouver, British Columbia, Canada, V6Z 2K5
    • Ontario
      • Hamilton, Ontario, Canada, L8N 4A6
      • Mississauga, Ontario, Canada, L5M 4N4
  • Forente stater
    • Alabama
      • Birmingham, Alabama, Forente stater, 35294
    • California
      • La Jolla, California, Forente stater, 92037-1030
      • Lancaster, California, Forente stater, 93534
      • Long Beach, California, Forente stater, 90822
      • Los Angeles, California, Forente stater, 90048
      • Los Angeles, California, Forente stater, 90057
      • Sacramento, California, Forente stater, 95817
      • Sacramento, California, Forente stater, 95816
      • San Diego, California, Forente stater, 92103-8465
      • Torrance, California, Forente stater, 90505
    • Colorado
      • Aurora, Colorado, Forente stater, 80045
    • Florida
      • Jacksonville, Florida, Forente stater, 32256
      • Orlando, Florida, Forente stater, 32803
    • Georgia
      • Atlanta, Georgia, Forente stater, 30308
      • Marietta, Georgia, Forente stater, 30060
    • Hawaii
      • Honolulu, Hawaii, Forente stater, 96813
    • Louisiana
      • Baton Rouge, Louisiana, Forente stater, 70890
      • Opelousas, Louisiana, Forente stater, 70520
    • Massachusetts
      • Boston, Massachusetts, Forente stater, 02114
    • Mississippi
      • Tupelo, Mississippi, Forente stater, 38801
    • Missouri
      • St Louis, Missouri, Forente stater, 63110
      • St Louis, Missouri, Forente stater, 63104
    • New Jersey
      • Egg Harbour Township, New Jersey, Forente stater, 08234
      • Hackensack, New Jersey, Forente stater, 07601
    • New Mexico
      • Albuquerque, New Mexico, Forente stater, 87131
    • New York
      • New York, New York, Forente stater, 10016
      • Syracuse, New York, Forente stater, 13210
    • North Carolina
      • Asheville, North Carolina, Forente stater, 28801
      • Chapel Hill, North Carolina, Forente stater, 27599-7080
      • Winston-salem, North Carolina, Forente stater, 27103
    • Oklahoma
      • Oklahoma City, Oklahoma, Forente stater, 73112-4481
    • Oregon
      • Portland, Oregon, Forente stater, 97239
    • Tennessee
      • Kingsport, Tennessee, Forente stater, 37660
    • Texas
      • Fort Sam Houston, Texas, Forente stater, 78234-3879
    • Utah
      • Salt Lake City, Utah, Forente stater, 84132
    • Virginia
      • Charlottesville, Virginia, Forente stater, 22908
      • Fairfax, Virginia, Forente stater, 22031
      • Richmond, Virginia, Forente stater, 23249
  • Mexico
      • Guadalajara, Mexico, 44160
      • Guadalajara, Mexico, 44670
      • Mexicali, Mexico, 21000
      • Mexico City, Mexico, 14050
      • Mexico Df, Mexico, 11649
      • Puebla, Mexico, 72560
  • Puerto Rico
      • Santurce, Puerto Rico, 00909
  • Sveits
      • Lausanne, Sveits, 1005
      • Lugano, Sveits, 6903
      • St. Gallen, Sveits, 9007
      • Zürich, Sveits, 8091
  • Tyskland
      • Berlin, Tyskland, 13353
      • Berlin, Tyskland, 10969
      • Bonn, Tyskland, 53127
      • Düsseldorf, Tyskland, 40225
      • Düsseldorf, Tyskland, 40237
      • Frankfurt Am Main, Tyskland, 60590
      • Freiburg, Tyskland, 79106
      • Giessen, Tyskland, 35392
      • Hamburg, Tyskland, 20099
      • Heidelberg, Tyskland, 69120
      • Jena, Tyskland, 07747
      • Kiel, Tyskland, 24105
      • Köln, Tyskland, 50937
      • Mainz, Tyskland, 55101
      • München, Tyskland, 81675
      • Offenburg, Tyskland, 77654
      • Tübingen, Tyskland, 72076
      • ULM, Tyskland, 89081
  • Østerrike
      • Graz, Østerrike, 8036
      • Innsbruck, Østerrike, 6020
      • Linz, Østerrike, 4010
      • Oberndorf, Østerrike, 5110
      • Wien, Østerrike, 1160
      • Wien, Østerrike, 1090

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • adult patients, >=18 years of age;
  • serological evidence of chronic hepatitis C (CHC);
  • CHC genotype 2 or 3;
  • receiving PEGASYS + Copegus according to local standard of care and no rapid viral response (RVR);
  • compensated liver disease.

Exclusion Criteria:

  • pegylated interferon, standard interferon or ribavirin therapy at any time prior to initiation of current therapy with PEGASYS + Copegus;
  • coinfection with hepatitis A or B, or human immunodeficiency virus (HIV);
  • history or other evidence of decompensated liver disease.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: PEG-IFN alfa-2a + Ribavirin for 24 weeks
After 24 weeks of treatment with pegylated interferon alfa-2a (PEG-IFN alfa-2a) 180 μg/week plus ribavirin 800-1200 mg/day participants who achieved at least a 2-log10 drop of hepatitis C virus (HCV) ribonucleic acid (RNA) at Week 12 (as compared to HCV RNA levels prior to treatment initiation) or had HCV RNA <15 IU/mL, and who were still taking study medication at treatment Week 24 were randomized into the study, at which time treatment was stopped. Participants were followed for an additional 48 weeks during the treatment-free follow-up period.
Legemiddel: Ribavirin
Andre navn:
  • Copegus®
Legemiddel: peginterferon alfa-2a
Andre navn:
  • Pegasys®
  • PEG-IFN alfa-2a
Aktiv komparator: PEG-IFN alfa-2a + Ribavirin for 48 weeks
After 24 weeks of treatment with PEG-IFN alfa-2a 180 μg/week plus ribavirin 800-1200 mg/day participants who achieved at least a 2-log10 drop of HCV RNA at Week 12 (as compared to HCV RNA levels prior to treatment initiation) or had HCV RNA <15 IU/mL, and who were still taking study medication at treatment Week 24 were randomized into the study, and continued treatment for another 24 weeks (for a total of 48 weeks of treatment). Participants were followed for an additional 24 weeks during the treatment-free follow-up period.
Legemiddel: Ribavirin
Andre navn:
  • Copegus®
Legemiddel: peginterferon alfa-2a
Andre navn:
  • Pegasys®
  • PEG-IFN alfa-2a

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Percentage of Participants With a Sustained Virologic Response 24 Weeks After Scheduled Completion of Treatment
Tidsramme: 24 weeks after scheduled treatment completion (approximately Week 48 for participants in the 24-week treatment group and Week 72 for participants in the 48-week treatment group.

Sustained virological response (SVR) is defined as a single last HCV RNA measurement <15 IU/ml (measured using the Roche COBAS AmpliPrep / COBAS TaqMan HCV Test) 24 weeks after scheduled treatment completion, defined as Week 44 or later for participants randomized to the 24-week treatment period or Week 68 or later for participants randomized to the 48-week treatment period.

Participants without measurements at the end of the 24-week untreated follow-up period were considered non-responders in the analysis.
24 weeks after scheduled treatment completion (approximately Week 48 for participants in the 24-week treatment group and Week 72 for participants in the 48-week treatment group.
Percentage of Participants With a Sustained Virologic Response 24 Weeks After Actual End of Treatment
Tidsramme: 24 weeks after actual end of treatment (range from Week 48 to Week 72).
Sustained virological response (SVR) is defined as a single last HCV RNA measurement <15 IU/ml (measured using the Roche COBAS AmpliPrep / COBAS TaqMan HCV Test) at 24 weeks after actual end of study treatment. For participants in the 48-week treatment group who stopped study treatment prior to Week 48 for any reason, the HCV RNA measurements 24 weeks after actual end of treatment were used in the analysis. Participants without a 24-week post treatment measurement are considered non-responders.
24 weeks after actual end of treatment (range from Week 48 to Week 72).

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Percentage of Participants With Virological Response 72 Weeks After Treatment Initiation
Tidsramme: Week 72

Virological response 72 weeks after treatment initiation is defined as the percentage of participants with HCV RNA <15 IU/mL as measured by the Roche COBAS AmpliPrep / COBAS TaqMan® HCV Test at 48 weeks post completion of the 24 week treatment period and 24 weeks post completion of the 48 week treatment period.

Participants without Week 72 measurements were considered non-responders in the analysis.
Week 72
Percentage of Participants With Virological Response at End of Treatment
Tidsramme: End of Treatment (Week 24 and Week 48 for each treatment group respectively).
Virological response at the end of treatment was defined as the percentage of participants with HCV RNA <15 IU/mL as measured by the Roche COBAS AmpliPrep / COBAS TaqMan® HCV Test after the last dose of study medication.
End of Treatment (Week 24 and Week 48 for each treatment group respectively).
Percentage of Participants With Virological Relapse
Tidsramme: End of treatment (Weeks 24 or 48) and 24 weeks after the end of treatment (weeks 48 and 72 in each treatment group respectively).

Virological relapse defined as the percentage of participants with a virological response at end of treatment but who did not have a sustained virological response 24 weeks after the end of treatment.

Virological response at end of treatment is defined as a single last HCV RNA measurement <15 IU/ml measured using the Roche COBAS AmpliPrep / COBAS TaqMan HCV Test at the day of last dose of study medication.

Sustained virological response 24 weeks after the actual treatment end (SVR24) is defined as a single last HCV RNA measurement <15 IU/ml at least 20 weeks after treatment end.
End of treatment (Weeks 24 or 48) and 24 weeks after the end of treatment (weeks 48 and 72 in each treatment group respectively).
Percentage of Participants With a Sustained Virologic Response 12 Weeks After Actual End of Treatment
Tidsramme: 12 weeks after actual end of treatment (range from Week 36 to Week 60)
Sustained virological response (SVR) is defined as a single last HCV RNA measurement <15 IU/ml (measured using the Roche COBAS AmpliPrep / COBAS TaqMan HCV Test) at 12 weeks after actual end of study treatment. For participants in the 48-week treatment group who stopped study treatment prior to Week 48 for any reason, the HCV RNA measurements 12 weeks after actual end of treatment were used in the analysis. Participants without a 12-week post treatment measurement are considered non-responders.
12 weeks after actual end of treatment (range from Week 36 to Week 60)
Number of Participants With Adverse Events (AEs)
Tidsramme: From Week 1 through Week 72.
An AE was defined as a sign or symptom, including intercurrent illness, that occurred during the course of the clinical study after treatment had started. A related AE is an event assessed by the Investigator to be remotely, possibly, or probably related to study treatment according to criteria provided in the protocol. A severe AE was an event graded by the Investigator as "incapacitating with inability to work or perform normal daily activity". A serious AE (SAE) was defined as any experience that suggests a significant hazard, contraindication, side effect or precaution. This includes any experience which was fatal; was life-threatening; required inpatient hospitalization or prolongation of an existing hospitalization; resulted in persistent or significant disability/incapacity; was a congenital anomaly/ birth defect; was medically significant or required intervention to prevent one or other of the outcomes listed above.
From Week 1 through Week 72.

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Hoffmann-La Roche

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart

1. juni 2008

Primær fullføring (Faktiske)

1. mai 2012

Studiet fullført (Faktiske)

1. mai 2012

Datoer for studieregistrering

Først innsendt

18. februar 2008

Først innsendt som oppfylte QC-kriteriene

18. februar 2008

Først lagt ut (Anslag)

26. februar 2008

Oppdateringer av studieposter

Sist oppdatering lagt ut (Anslag)

22. juli 2013

Siste oppdatering sendt inn som oppfylte QC-kriteriene

15. juli 2013

Sist bekreftet

1. juli 2013

Mer informasjon

Begreper knyttet til denne studien

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • MV21371
  • 2007-004993-15

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere